Background The rationale behind this update of the 2016 British Society for Rheumatology
(BSR) guidelines on prescribing anti-rheumatic drugs in pregnancy and breastfeeding [1, 2] …

Inflammatory bowel disease (IBD) has a peak age of diagnosis before the age of 35 years.
Concerns about infertility, adverse pregnancy outcomes, and heritability of IBD have …

2. Methods This document represents the third version of the European Consensus on
reproduction in IBD. The development of this Consensus included the formulation of …

Background: Psoriasis is a common chronic inflammatory skin disease with an exceptionally
high burden for women. Objective: Sex-dependent differences in disease manifestation …

Abstract Background and Aims Filgotinib is a small molecule that selectively inhibits Janus
kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is …

Abstract Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In
addition to treatment effectiveness, it is important to define and understand the long-term …

Anti-TNF therapy has been successfully used as first-line biologic treatment for moderate-to-
severe inflammatory bowel disease (IBD), in both 'step-up'and 'top-down'approaches, and …

Background The optimal choice of biological agents after failure of anti‐tumour‐necrosis‐
factor‐(TNF) α agent in Crohn's disease (CD) is yet to be defined. Aims To assess the …

Background Ustekinumab is increasingly used in pregnant women with inflammatory bowel
disease (IBD). Existing safety data are reassuring, but the stability of ustekinumab levels in …

Abstract Background and Aims Evidence on the safety of newer biologics during pregnancy
is limited. We aimed to assess the safety of ustekinumab and vedolizumab treatment during …